Literature DB >> 23550732

Generation of neural cells from DM1 induced pluripotent stem cells as cellular model for the study of central nervous system neuropathogenesis.

Guangbin Xia1, Katherine E Santostefano, Marianne Goodwin, Jilin Liu, S H Subramony, Maurice S Swanson, Naohiro Terada, Tetsuo Ashizawa.   

Abstract

Dystrophia myotonica type 1 (DM1) is an autosomal dominant multisystem disorder. The pathogenesis of central nervous system (CNS) involvement is poorly understood. Disease-specific induced pluripotent stem cell (iPSC) lines would provide an alternative model. In this study, we generated two DM1 lines and a normal iPSC line from dermal fibroblasts by retroviral transduction of Yamanaka's four factors (hOct4, hSox2, hKlf4, and hc-Myc). Both DM1 and control iPSC clones showed typical human embryonic stem cell (hESC) growth patterns with a high nuclear-to-cytoplasm ratio. The iPSC colonies maintained the same growth pattern through subsequent passages. All iPSC lines expressed stem cell markers and differentiated into cells derived from three embryonic germ layers. All iPSC lines underwent normal neural differentiation. Intranuclear RNA foci, a hallmark of DM1, were detected in DM1 iPSCs, neural stem cells (NSCs), and terminally differentiated neurons and astrocytes. In conclusion, we have successfully established disease-specific human DM1 iPSC lines, NSCs, and neuronal lineages with pathognomonic intranuclear RNA foci, which offer an unlimited cell resource for CNS mechanistic studies and a translational platform for therapeutic development.

Entities:  

Mesh:

Year:  2013        PMID: 23550732      PMCID: PMC3616452          DOI: 10.1089/cell.2012.0086

Source DB:  PubMed          Journal:  Cell Reprogram        ISSN: 2152-4971            Impact factor:   1.987


  66 in total

Review 1.  Induced pluripotent stem cells and reprogramming: seeing the science through the hype.

Authors:  Juan Carlos Izpisúa Belmonte; James Ellis; Konrad Hochedlinger; Shinya Yamanaka
Journal:  Nat Rev Genet       Date:  2009-10-27       Impact factor: 53.242

2.  Site-specific gene correction of a point mutation in human iPS cells derived from an adult patient with sickle cell disease.

Authors:  Jizhong Zou; Prashant Mali; Xiaosong Huang; Sarah N Dowey; Linzhao Cheng
Journal:  Blood       Date:  2011-08-31       Impact factor: 22.113

Review 3.  Myotonic dystrophy mouse models: towards rational therapy development.

Authors:  Mário Gomes-Pereira; Thomas A Cooper; Geneviève Gourdon
Journal:  Trends Mol Med       Date:  2011-07-02       Impact factor: 11.951

4.  Viral vector producing antisense RNA restores myotonic dystrophy myoblast functions.

Authors:  D Furling; G Doucet; M-A Langlois; L Timchenko; E Belanger; L Cossette; J Puymirat
Journal:  Gene Ther       Date:  2003-05       Impact factor: 5.250

5.  Anterior temporal white matter lesions in myotonic dystrophy with intellectual impairment: an MRI and neuropathological study.

Authors:  A Ogata; S Terae; M Fujita; K Tashiro
Journal:  Neuroradiology       Date:  1998-07       Impact factor: 2.804

6.  Myotonic dystrophy in transgenic mice expressing an expanded CUG repeat.

Authors:  A Mankodi; E Logigian; L Callahan; C McClain; R White; D Henderson; M Krym; C A Thornton
Journal:  Science       Date:  2000-09-08       Impact factor: 47.728

7.  Mutant human embryonic stem cells reveal neurite and synapse formation defects in type 1 myotonic dystrophy.

Authors:  Antoine Marteyn; Yves Maury; Morgane M Gauthier; Camille Lecuyer; Remi Vernet; Jérôme A Denis; Geneviève Pietu; Marc Peschanski; Cécile Martinat
Journal:  Cell Stem Cell       Date:  2011-03-31       Impact factor: 24.633

8.  Pentamidine reverses the splicing defects associated with myotonic dystrophy.

Authors:  M Bryan Warf; Masayuki Nakamori; Catherine M Matthys; Charles A Thornton; J Andrew Berglund
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-12       Impact factor: 11.205

9.  Intellectual and cognitive function in adults with myotonic muscular dystrophy.

Authors:  M M Portwood; J J Wicks; J S Lieberman; M J Duveneck
Journal:  Arch Phys Med Rehabil       Date:  1986-05       Impact factor: 3.966

10.  Foci of trinucleotide repeat transcripts in nuclei of myotonic dystrophy cells and tissues.

Authors:  K L Taneja; M McCurrach; M Schalling; D Housman; R H Singer
Journal:  J Cell Biol       Date:  1995-03       Impact factor: 10.539

View more
  24 in total

Review 1.  The Histochemistry and Cell Biology omnium-gatherum: the year 2015 in review.

Authors:  Douglas J Taatjes; Jürgen Roth
Journal:  Histochem Cell Biol       Date:  2016-02-15       Impact factor: 4.304

2.  Elimination of Toxic Microsatellite Repeat Expansion RNA by RNA-Targeting Cas9.

Authors:  Ranjan Batra; David A Nelles; Elaine Pirie; Steven M Blue; Ryan J Marina; Harrison Wang; Isaac A Chaim; James D Thomas; Nigel Zhang; Vu Nguyen; Stefan Aigner; Sebastian Markmiller; Guangbin Xia; Kevin D Corbett; Maurice S Swanson; Gene W Yeo
Journal:  Cell       Date:  2017-08-10       Impact factor: 41.582

3.  Furamidine Rescues Myotonic Dystrophy Type I Associated Mis-Splicing through Multiple Mechanisms.

Authors:  Jana R Jenquin; Leslie A Coonrod; Quinn A Silverglate; Natalie A Pellitier; Melissa A Hale; Guangbin Xia; Masayuki Nakamori; J Andrew Berglund
Journal:  ACS Chem Biol       Date:  2018-08-27       Impact factor: 5.100

Review 4.  Modeling simple repeat expansion diseases with iPSC technology.

Authors:  Edyta Jaworska; Emilia Kozlowska; Pawel M Switonski; Wlodzimierz J Krzyzosiak
Journal:  Cell Mol Life Sci       Date:  2016-06-03       Impact factor: 9.261

5.  A CTG repeat-selective chemical screen identifies microtubule inhibitors as selective modulators of toxic CUG RNA levels.

Authors:  Kaalak Reddy; Jana R Jenquin; Ona L McConnell; John D Cleary; Jared I Richardson; Belinda S Pinto; Maja C Haerle; Elizabeth Delgado; Lori Planco; Masayuki Nakamori; Eric T Wang; J Andrew Berglund
Journal:  Proc Natl Acad Sci U S A       Date:  2019-09-30       Impact factor: 11.205

Review 6.  Modeling diseases of noncoding unstable repeat expansions using mutant pluripotent stem cells.

Authors:  Shira Yanovsky-Dagan; Hagar Mor-Shaked; Rachel Eiges
Journal:  World J Stem Cells       Date:  2015-06-26       Impact factor: 5.326

7.  Cell therapy in Brazil: time for reflection.

Authors:  Milton Artur Ruiz
Journal:  Rev Bras Hematol Hemoter       Date:  2013

8.  Genome modification leads to phenotype reversal in human myotonic dystrophy type 1 induced pluripotent stem cell-derived neural stem cells.

Authors:  Guangbin Xia; Yuanzheng Gao; Shouguang Jin; S H Subramony; Naohiro Terada; Laura P W Ranum; Maurice S Swanson; Tetsuo Ashizawa
Journal:  Stem Cells       Date:  2015-06       Impact factor: 6.277

9.  Genome Therapy of Myotonic Dystrophy Type 1 iPS Cells for Development of Autologous Stem Cell Therapy.

Authors:  Yuanzheng Gao; Xiuming Guo; Katherine Santostefano; Yanlin Wang; Tammy Reid; Desmond Zeng; Naohiro Terada; Tetsuo Ashizawa; Guangbin Xia
Journal:  Mol Ther       Date:  2016-05-12       Impact factor: 11.454

10.  Impeding Transcription of Expanded Microsatellite Repeats by Deactivated Cas9.

Authors:  Belinda S Pinto; Tanvi Saxena; Ruan Oliveira; Héctor R Méndez-Gómez; John D Cleary; Lance T Denes; Ona McConnell; Juan Arboleda; Guangbin Xia; Maurice S Swanson; Eric T Wang
Journal:  Mol Cell       Date:  2017-10-19       Impact factor: 17.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.